miR‑148a modulates the viability, migration and invasion of oral squamous cell carcinoma cells by regulating HLA‑G expression

Zhang, Yuying; Jin, Xin; Wang, Jie

doi:10.3892/mmr.2019.10280

Cited by 10 publications

(13 citation statements)

References 46 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We [ 9 ] and others [ 43 ] have reported discrepancies between HLA-G mRNA and protein expression in cancer. Recent studies suggested that HLA-G is heavily post-transcriptionally regulated [ 44 , 45 ], in which miRNA may play an important role [ 46 , 47 ]. For instance, a study on renal cell carcinoma showed strong post-transcriptional gene regulation of HLA-G by miRNA-152, miRNA-148A, miRNA-148B, and miRNA-133A [ 48 ].…”

Section: Expression Of Hla-g In Cancermentioning

confidence: 99%

HLA-G: A New Immune Checkpoint in Cancer?

Krijgsman

Roelands

Hendrickx

et al. 2020

IJMS

View full text Add to dashboard Cite

Human leukocyte antigen G (HLA-G), known as a central protein in providing immune tolerance to the fetus in pregnant women, is also studied for a possible role in tumor development. Many studies have claimed HLA-G as a new immune checkpoint in cancer. Therefore, HLA-G and its receptors might be targets for immune checkpoint blockade in cancer immunotherapy. In order to substantiate that HLA-G is indeed an immune checkpoint in cancer, two important questions need to be answered: (1) To what extent is HLA-G expressed in the tumor by cancer cells? and (2) What is the function of HLA-G in cancer immune evasion? In this review, we discuss these questions. We agree that HLA-G is a potentially new immune checkpoint in cancer, but additional evidence is required to show the extent of intra-tumor and inter-tumor expression. These studies should focus on tumor expression patterns of the seven different HLA-G isoforms and of the receptors for HLA-G. Furthermore, specific roles for the different HLA-G isoforms should be established.

show abstract

Section: Expression Of Hla-g In Cancermentioning

confidence: 99%

HLA-G: A New Immune Checkpoint in Cancer?

Krijgsman

Roelands

Hendrickx

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Multiple studies have shown that transfection of HLA-G positive cell lines with either microRNA (miRNA), short hairpin RNA (shRNA) or small interference RNA (siRNA) led to reduced mRNA and protein expression of HLA-G [ 104 , 105 , 106 , 107 ]. The viability, migration and invasion of oral squamous cell carcinoma (OSCC) cells were reduced as a result of decreased expression of HLA-G after transfection with a miRNA mimic [ 108 ]. This suggests that RNAi can be used to reduce HLA-G expression on tumor cells and, subsequently, inhibit its tumor-promoting effects.…”

Section: Hla-g As Target For Immune Checkpoint Inhibition In Cancementioning

confidence: 99%

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Attia

Dessens

Water

et al. 2020

IJMS

View full text Add to dashboard Cite

Human leukocyte antigen G (HLA-G) mediates maternal-fetal immune tolerance. It is also considered an immune checkpoint in cancer since it may mediate immune evasion and thus promote tumor growth. HLA-G is, therefore, a potential target for immunotherapy. However, existing monoclonal antibodies directed against HLA-G lack sufficient specificity and are not suitable for immune checkpoint inhibition in a clinical setting. For this reason, it is essential that alternative approaches are explored to block the interaction between HLA-G and its receptors. In this review, we discuss the structure and peptide presentation of HLA-G, and its interaction with the receptors Ig-like transcript (ILT) 2, ILT4, and Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4). Based on our findings, we propose three alternative strategies to block the interaction between HLA-G and its receptors in cancer immunotherapy: (1) prevention of HLA-G dimerization, (2) targeting the peptide-binding groove of HLA-G, and (3) targeting the HLA-G receptors. These strategies should be an important focus of future studies that aim to develop immune checkpoint inhibitors to block the interaction between HLA-G and its receptors for the treatment of cancer.

show abstract

“…The increase in miR-148a expression in the current study may be considered as oncogenes or tumor suppressors depending on their interaction with specific targets, the miR-148a inhibits the gene expression of HLA-G as its target gene, and thus prevent the inhibition of the work of natural killer cells, this is a defensive way for the body to reduce the severity and progression of the disease. HLA-G interacts with miR-148a to suppress oral squamous cell carcinoma leading to inhibiting the migration and invasion and thus, miR-148a/HLA-G interaction may be a therapeutic strategy for OSCC oral squamous cell carcinoma [19]. That the anticancer effect mediated by miR-148a depends on the inhibition of STAT3 and Akt that regulate pathways contributing to cell proliferation and migration.…”

Section: Discussionmentioning

confidence: 99%

Measuring The Level of MIR-148A in Iraqi Women Diagnosed with Breast Cancer

Al-Mashhadani¹,

Mahood²,

Abassi³

2022

PJMHS

View full text Add to dashboard Cite

Background: Breast cancer is the most common type of cancer in Iraq, and the incidence of it has increased among Iraqi women in the past two decades, as it represents one of the most important threats to women's health. Aim: this study aimed to investigate the miR-148a gene expression as a biomarker in different age groups of Iraqi women with breast cancer, as well as its association with patient characteristics such as body mass index, disease stage, and tumor location. Method: Fifty women diagnosed with breast cancer were enrolled in this study in addition to 25 healthy individuals as a control group. The fold expression (FE) of miRNA-148a was detected by quantitative polymerase chain reaction (qPCR) techniques. Results: The results showed the highest significant difference in the gene expression of miR-148a in breast cancer patients in the age group (50) compared to the control group, and the difference was significant in the age group (<40) compared to the control group, highly significant differences was found in the age group (40-49) compared with the control group. The results also showed no significant differences in the fold level of gene expression for miR-148a in the grades (I, II, and III) of breast cancer patients, and that the highest level was recorded in the second grade, and the highest level was recorded in the grade. Keywords: Breast Cancer, miR-148a, BMI

show abstract

miR‑148a modulates the viability, migration and invasion of oral squamous cell carcinoma cells by regulating HLA‑G expression

Cited by 10 publications

References 46 publications

HLA-G: A New Immune Checkpoint in Cancer?

HLA-G: A New Immune Checkpoint in Cancer?

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Measuring The Level of MIR-148A in Iraqi Women Diagnosed with Breast Cancer

Contact Info

Product

Resources

About